This content is machine translated Moderate to severe atopic dermatitis Biologic therapy in the changing times: “Best practice” approaches in focus In addition to the new systemic drugs recently launched, several active substances are currently in development. These include some biologics in advanced stages of clinical testing. Overall, the future prospects…
View Post 4 min This content is machine translated Atopic dermatitis JAK inhibition as a mode of action – an update. Janus kinase (JAK) inhibitors are a promising new treatment option for adult patients with atopic eczema, given their rapid relief of pruritus and inflammatory lesions. In addition to baricitinib, which…
View Post 3 min This content is machine translated "Small Molecules" for the Treatment of Psoriasis Oral and topical drug candidates score well in studies As in today’s era of personalized medicine a treatment tailored to the individual needs of psoriasis patients is important, there are several arguments for a use of small molecule substances.…
View Post 12 min This content is machine translated Atopic dermatitis Digital support options for treatment The terms atopic dermatitis, atopic eczema and atopic dermatitis stand for a global skin disease, with children and adolescents being the most frequently affected. In 2020, a systematic review included… CME-Test
View Post 3 min This content is machine translated Apremilast Effective reduction of itching in the context of scalp psoriasis Visible pruritic lesions on the scalp are a major stress factor for many psoriasis patients. Topical preparations are used as first-line therapy, but these are not always effective, especially in…
View Post 3 min This content is machine translated Phase IIa study Tocilizumab for the treatment of Schnitzler syndrome Schnitzler syndrome is a rare autoinflammatory disorder. Core symptoms include chronic, recurrent hives. In particular, for patients who do not respond to anti-IL1 therapy, there is a need for new…
View Post 4 min This content is machine translated The somewhat different knowledge Who was actually… Moriz Kaposi? When Moriz Kaposi first described Kaposi’s sarcoma in 1872, he probably had no idea that this entity would become much more famous in the context of HIV/AIDS. He was much…
View Post 5 min This content is machine translated Psoriatic Arthritis New long-term data on guselkumab published Phase III data on the IL23p19 inhibitor guselkumab demonstrate complete resolution of skin symptoms and positive joint effects in adult patients with active psoriatic arthritis (PsoA) lasting over two years.
View Post 3 min This content is machine translated Studies in focus Interleukin-31 as a clinical target in prurigo nodularis. For the treatment of prurigo nodularis, there are rather few approved therapeutic options available today. There is a need for new effective and well-tolerated treatment options. The use of the…
View Post 6 min This content is machine translated Psoriasis as an inflammatory systemic disease Changing disease concept – implications for biologic therapy. Psoriasis is nowadays no longer understood as an exclusive skin disease, but rather as a systemic disease. Biologics specifically intervene in the disease process and have revolutionized treatment options. When…
View Post 1 min This content is machine translated Webinar Relevant aspects for the management of atopic dermatitis By way of introduction, the experts will present the principles of action of the new system therapies, the “disease burden” & comorbidities of atopic dermatitis. This will be followed by…
